🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-523791-24-00
Authorised Phase I

A study investigating the effect of curcumin on the absorption and elimination of IMU 838, a new compound that may potentially be used in the treatment of multiple sclerosis, and the effect of IMU 838 on the absorption and elimination of rosuvastatin.

2025-523791-24-00 · tracked via the Priya Life Science EU tracker
Sponsor
Immunic AG
Sponsor type
Pharmaceutical company
Therapeutic area
Nervous System Diseases
Decision date
17/12/2025
Enrollment target
28
Sites
Netherlands

Condition studied

Multiple sclerosis

Eligibility

Age group
18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523791-24-00 on CTIS ↗ ← All trials in the EU